German Bundesrat OKs health reform bill

5 March 2007

The German Upper House, the Bundesrat, has completed the passage of the controversial health service reform which will now be introduced on April 1. A total of 11 federal states had already indicated support before the parliamentary hearing of the bill but the right-wing and liberal coalition of the states of Baden-Wuerttemberg, Lower Saxony and North Rhine-Westphalia together with Berlin and Saxony agreed to vote against the measure.

The Lower House, the Bundestag passed the bill in early February. The core of the reform is the creation of a national health fund as a central point for the collection of contributions together with an agreed nationwide level of health fund member contributions. The health funds will draw additional money required from the national pot but, if this is not sufficient and the fund cannot manage its resources, then patients may well have to pay extra charges levied by their particular organization.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight